Overview of Tilidin comp. STADA

Quick Facts

Property	Description
Active ingredients	Tilidine, Naloxone Hydrochloride
Form	Oral solid dosage form (e.g., tablet)
Pharmacological class	Opioid Analgesic and Opioid Antagonist Combination
Common use	Potent pain relief
Origin	Synthetic

What Type of Medicine is Tilidin comp. STADA?

Tilidin comp. STADA is a prescription-only medicine defined as a synthetic fixed-dose combination product for powerful pain relief. The primary analgesic, Tilidine, is a synthetic opioid prodrug categorized as an Opioid analgesic. This specific preparation, manufactured by STADA, is clinically recognized for its dual structure where the opioid component is combined with the opioid antagonist Naloxone Hydrochloride. This formulation is positioned for patients whose pain necessitates management with a strong, centrally acting medication.

Composition and Form: What is Tilidin comp. STADA Made Of?

The medicine contains two distinct active ingredients: Tilidine and Naloxone Hydrochloride. The Tilidine component provides central-acting pain-relieving effects, while the Naloxone serves as a competitive opioid receptor antagonist. It is typically supplied as an oral solid dosage form, most commonly a tablet or film-coated tablet, which is critical for its function. The preparation is intended strictly for oral administration, a differentiating factor that ensures the full therapeutic benefit is achieved.

Why the Combination? Understanding the General Purpose

The general purpose of this specific formulation is to achieve potent pain relief while simultaneously incorporating a mechanism to limit the potential for non-oral misuse. Tilidine provides the essential analgesic effect, acting centrally to modify the body's perception of severe pain. The Naloxone component is deliberately included as an abuse-deterrent measure. The combination of an opioid agonist with an antagonist is a validated strategy to minimize the potential for abuse. When the medicine is taken correctly by mouth, Naloxone is largely inactivated; however, if the tablet is misused via injection, the Naloxone becomes fully active, swiftly negating the effects of the opioid.

Regulatory References

NIH Drug Info (Naloxone)

What side effects are possible with Tilidin comp. STADA?

Possible Side Effects and Safety Information

The safety profile of Tilidin comp. STADA is defined by adverse effects classified by frequency and body system, as documented in official regulatory sources such as the Summary of Product Characteristics (SmPC).

Frequency Classification of Adverse Reactions

The most frequently documented side effects are categorized as Very Common or Frequent.

Very Common: Nausea and vomiting are the most common adverse reactions, often observed at the beginning of treatment.
Frequent (Common): Effects include dizziness, drowsiness, headache, fatigue, nervousness, diarrhea, abdominal pain, and increased sweating (hyperhidrosis).

Less frequently documented reactions include pronounced somnolence, classified as Uncommon. Other effects, such as hallucinations, confusional state, tremor, and euphoric mood, have been reported with an Unknown Frequency.

Serious Adverse Reactions and Safety Constraints

The product's combination structure introduces specific safety considerations, particularly concerning the opioid antagonist, Naloxone.

Serious Adverse Potential: The most significant safety risk is the potential for severe opioid withdrawal syndrome if the medication is used by individuals dependent on opiates or if it is administered via a non-oral route. Severe reactions, including respiratory depression and cardiovascular events, are documented in regulatory information.
Population Constraint: The medicine is contraindicated in patients with severe hepatic insufficiency (severe liver impairment). In this population, the metabolism of the active components is compromised, leading to an unfavorable alteration in the drug's intended action and safety characteristics.
Drug Interaction Safety Pattern: Concomitant use with specific inhibitors of liver enzymes (e.g., CYP3A4 inhibitors) is noted to increase the risk of amplified effects, potentially leading to a heightened risk of respiratory depression.

Overdose and Emergency Response

Overdose and when to seek help

Overdose with Tilidin comp. STADA is defined by the toxic effects of the potent opioid component (Tilidine) and the subsequent actions of the antagonist (Naloxone).

Documented Manifestations and Severe Outcomes

Overdose may present with severe central nervous system (CNS) depression, including profound drowsiness, loss of consciousness, and miosis (pinpoint pupils). The primary life-threatening manifestation is respiratory depression (slowed or stopped breathing), which can lead to apnea. Severe outcomes documented following reversal include cardiovascular events like hypotension or ventricular arrhythmias, and the development of pulmonary edema. Misuse in opioid-dependent individuals is known to precipitate a severe acute opioid withdrawal syndrome, a circumstance specifically noted in regulatory information.

Mandated Emergency Action

Immediate emergency medical assistance must be sought immediately if an overdose is suspected. The use of an opioid antagonist is the documented procedural step for reversal, but regulatory documents explicitly state that this is not a substitute for professional emergency medical care. Patients must be kept under continued surveillance until medical care is available. This continuous monitoring is required due to the documented risk of symptoms returning (relapse) and the need for prolonged observation, especially in cases of renal or hepatic impairment.

Therapeutic Uses of Tilidin comp. STADA

What Tilidin comp. STADA Treats: Main Uses and Benefits

Management of Moderate to Severe Pain Unresponsive to Standard Analgesia

This medication is applied in situations involving moderate to severe pain that requires supportive, centrally acting relief. It is generally considered relevant for the long-term management of patients experiencing chronic pain. The medicine is used to manage pain when symptoms related to physical discomfort are generally considered relevant when symptoms create noticeable physiological strain and conventional management may be insufficient. A primary therapeutic benefit is the provision of supportive symptomatic relief, which generally helps ease the overall symptom burden of intense manifestations.

Use in Acute and Chronic Pain Contexts

This combination is relevant for easing the burden associated with postoperative pain, chronic pain syndromes, and pain linked to malignant conditions. This supportive intervention is generally reserved for established clinical contexts where significant discomfort is present, relevant when symptoms become temporarily overwhelming, and supportive symptomatic assistance is appropriate. It assists patients during phases of heightened symptomatic distress, helping patients cope more steadily and assisting with managing symptoms that interfere with daily functioning.

Quick Fact: Management Goal for Intense Pain

Property	Description
Symptom Type	Pain that is moderate to severe
Relief Goal	Contributes to easing the overall symptom load
Usage Context	Chronic, postoperative, and acute severe pain
Patient Benefit	Assists with managing symptoms that interfere with daily functioning

Eligibility and Restrictions for Use

The official regulatory profile for Tilidin comp. STADA strictly defines the patient populations eligible to use the medicine based on specific medical conditions and demographics.

Contraindicated Populations (Must Not Use)

Use of this medicine is formally contraindicated in patients with a known hypersensitivity to Tilidine, Naloxone, or any excipient. It must not be used by individuals with pre-existing opioid dependence or those in a state of acute intoxication (e.g., alcohol). The combination is also strictly prohibited for patients with severe hepatic impairment (severe liver dysfunction) and for children under 14 years of age.

Eligibility Restrictions and Special Caution

Eligibility is restricted in several specific groups. Patients with severe renal impairment or mild to moderate hepatic impairment require close monitoring and dose adjustment. Use is not recommended during the second and third trimesters of pregnancy or for regular use while breastfeeding. Older adults may use the medicine, but require special consideration and individual dose titration. Conditional use with caution is also required for patients with conditions such as increased intracranial pressure.

What should I know about interactions with other medicines?

Tilidin comp. STADA Interactions with other medicines and products

The official interaction profile is defined by the properties of its opioid component, Tilidine, and its potential for severe pharmacodynamic or pharmacokinetic alterations with co-administered substances. This information is based strictly on government regulatory documents.

Interaction Scope

Category	Details (Strictly Regulatory)
Medicinal product categories with documented interactions	CNS Depressants (including hypnotics, sedatives, and general anaesthetics); MAOIs; Serotonergic Drugs; CYP3A4 Inhibitors/Inducers; Alcohol.
Mechanistic basis of interactions	Pharmacodynamic Potentiation (additive CNS depression); Metabolic Alteration (CYP3A4 and CYP2C19 inhibition/induction, altering systemic exposure); Serotonergic Effects (risk of Serotonin Syndrome).
Timing-based interaction rules	Co-administration with MAOIs requires a mandatory 14-day washout period after the MAOI is discontinued.
Population-specific interaction notes	Elderly, cachectic, or debilitated patients are noted to have a heightened risk for severe interaction outcomes when CNS depressants are co-administered.

Interaction Classifications (High-Level)

Classification	Details (Strictly Regulatory)
Interaction severity classification	Contraindicated (MAOIs); Life-threatening Risk (CNS Depressants/Alcohol); Serious Risk (Serotonergic Agents).
Interaction-context constraints	The product's interaction profile is established for oral administration; the Naloxone component acts as a constraint, causing the precipitation of withdrawal if the medicine is misused by non-oral routes.

The official interaction statements classify co-administration with MAOIs as strictly prohibited, requiring a washout period. This regulatory structure emphasizes the potentiation of depressant effects when taken with alcohol and CNS depressants, alongside the importance of monitoring for alterations in systemic exposure caused by CYP450 inhibitors and inducers.

Mechanism of Action

Prodrug Activation via Hepatic Metabolism

Tilidin is an inactive prodrug that must first undergo metabolic transformation to exert its effect. This conversion occurs primarily within the liver, mediated by cytochrome P450 enzymes CYP3A4 and CYP2C19. This enzymatic process generates the active metabolite, nortilidine, which is the molecule responsible for the subsequent physiological adjustments.

μ-Opioid Receptor Engagement

The active metabolite, nortilidine, acts within the central nervous system by binding as an agonist to the μ-opioid receptors (MOR). This interaction represents a core mechanism of receptor-mediated signaling. Molecular engagement with the MOR modifies early neuronal steps, leading to the inhibition of key excitatory neurotransmitters involved in signal transmission.

️ Modulation of Neural Signaling Pathways

Agonism at the μ-opioid receptors initiates a downstream intracellular cascade that influences neuronal excitability. This action stabilizes the cell membrane by promoting neuronal hyperpolarization. This process decreases the cell's excitability threshold, thereby limiting signal propagation along the neural pathway. This key pathway effect leads to system-level physiological modulation that results from the receptor activation.

Dosage and Administration Information

Official Administration Guidelines

Tilidin comp. STADA is a fixed-dose combination product intended for oral administration only. The integrity of the dosage form is critical: sustained-release tablets must be swallowed whole and not crushed, chewed, or dissolved. This restriction is necessary to maintain the extended release of the analgesic and ensure the proper functioning of the abuse-deterrent system built into the formulation. Intake is generally independent of meals.

Dosing and Scheduling

Administration begins with individual dose titration to determine the necessary maintenance level, typically using lower-strength tablets or an oral solution in regions where it is available. Once the maintenance dose is established, sustained-release tablets are generally administered on a scheduled basis, most commonly twice daily (b.i.d.) with 12-hour intervals, for long-term chronic management. The maximum recommended daily dose (MDD) of the Tilidine component is 600 mg, as established by regulatory thresholds.

Procedural Adjustments

Specific dosage modifications are required for certain populations. In cases of severe hepatic impairment (severe liver disease), the dose must be cautiously adjusted or reduced. This adjustment is mandated due to potential changes in the metabolism of both Tilidine and Naloxone. The use of this medicine is generally not recommended in children under one year of age. If a dose is missed, patients should follow the standard protocol of taking it as soon as remembered, unless the time for the next scheduled dose is near, in which case the missed dose should be skipped to prevent a double dose.

Recent Clinical Evidence

Research evidence / Overview of studies for Tilidin comp. STADA

Evidence for use in Chronic Moderate to Severe Pain

Research examining Tilidin comp. STADA has been primarily applied in studies examining patient-reported experiences of those with pain that is persistent and moderate to severe. The evidence base includes a mix of long-term observational studies and shorter Randomized Controlled Trials (RCTs), with the latter often focusing on acute or experimental symptom patterns. These studies typically include adult populations and some specific cohorts of patients living with chronic pain and multimorbidity (multiple health conditions).

In these research scenarios, investigators were used in research exploring how symptoms change over time and how studies examined outcomes related to daily functioning or activity level. Long-term observational studies reported how symptoms evolved in the observed populations, and findings describe patterns observed in the studies related to patient-reported outcomes describing perceived discomfort. The long-term data also studies monitored physiological strain or stress and documented observations related to long-term tolerability.

However, the certainty around long-term use remains low. The evidence relies heavily on open-label and observational study designs for long-term data, which provides context but not individual predictions compared to large-scale, controlled trials. Furthermore, comparative evidence against other analgesic options over extended time periods remains limited, and high rates of patient discontinuation (drop-out) were noted in some multi-year studies, which may limit the completeness of the data.

Research on the Abuse-Deterrent Combination

Research examined the combination of Tilidine with Naloxone Hydrochloride for its intended role in discouraging non-oral misuse. The research approach focused on post-marketing surveillance and large-scale database analyses rather than traditional clinical trials. These studies research examined and reported the frequency of events related to misuse, abuse, and dependency, typically expressed as an incidence rate relative to the volume of the medicine dispensed.

These studies data show patterns related to misuse incidence and documented how patients reported their experience. The findings describe group patterns of misuse or dependency derived from large patient population data sets. Studies monitored reported patterns of misuse which were observed to differ between the oral solution formulation and the slow-release tablet formulation. The data analysis describes patterns observed in the studies related to misuse incidence across available forms.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Tilidin comp. STADA (FAQ)

Q: Is Tilidin comp. STADA considered a strong or weak painkiller?

A: According to official product information, Tilidin comp. STADA is classified as a synthetic opioid analgesic combination. This type of medication is indicated for the treatment of severe pain.

Q: How long can the pain relief effects of Tilidin comp. STADA last?

A: The sustained-release formulation is intended to provide coverage between the typically scheduled doses. Official guidelines state that these doses are usually administered twice daily, which means they are scheduled about 12 hours apart for maintenance therapy.

Q: Is it normal to feel tired or dizzy after taking Tilidin comp. STADA?

A: Yes, regulatory documents list dizziness and drowsiness as Frequent (Common) side effects. Due to these frequent effects, caution may be required when performing activities that require concentration.

Q: Does taking Tilidin comp. STADA cause constipation, and if so, why?

A: The formulation includes Naloxone, an opioid antagonist, which is intended to inhibit the opioid's effect on the bowel, a common source of constipation with opioid medication. However, as the medicine contains an opioid component, effects on gastrointestinal function are still possible.

Q: What are the most common side effects people report with Tilidin comp. STADA?

A: The most frequently documented side effects are Very Common nausea and vomiting, which are often observed when treatment is first started. Other Frequent (Common) effects reported in official documents include dizziness, headache, and drowsiness.

Q: Is it safe to take herbal supplements while using Tilidin comp. STADA?

A: Specific herbal supplements are not listed in the product information. However, official warnings state that the medicine interacts with certain liver enzymes, and some herbal supplements may affect these. Discussing the use of any herbal product with a healthcare professional is generally recommended to check for interaction potential.

Q: Does Tilidin comp. STADA affect the ability to drive or operate machinery?

A: Yes, due to the documented frequent side effects such as dizziness, drowsiness, and somnolence, the medicine can potentially impair a person's ability to drive or operate machinery. Official information warns that caution is necessary due to the potential for impairment.

Q: Is it safe for older adults to use Tilidin comp. STADA?

A: Official information states that older adults may use this medicine, but they require special consideration and individual dose management. They may also have an increased risk for severe interaction outcomes if taking co-administered Central Nervous System (CNS) depressant medications.

Q: Can people with liver problems safely use Tilidin comp. STADA?

A: Use is strictly contraindicated (prohibited) in patients who have severe hepatic impairment (severe liver disease). Individuals with mild to moderate liver impairment require close medical monitoring.

Q: What are the potential withdrawal symptoms associated with stopping Tilidin comp. STADA?

A: The medication carries a risk of opioid withdrawal syndrome. General symptoms of opioid withdrawal can include both physical and emotional signs such as nausea, vomiting, diarrhea, anxiety, and insomnia.

Q: What are the signs of a possible allergic reaction to Tilidin comp. STADA?

A: The medicine is contraindicated in patients with known hypersensitivity (severe allergy) to the active ingredients or other components. If signs of a serious allergic reaction are suspected, immediate medical attention is necessary.

Q: Why do some people experience nausea or vomiting when starting Tilidin comp. STADA?

A: Nausea and vomiting are documented as Very Common adverse reactions to this medicine. These effects are most often observed when a person is first starting treatment with the medication.

Q: Is it safe for people with asthma or breathing conditions?

A: Caution is necessary for patients with breathing conditions. Official warnings indicate that the Tilidine component is known to cause respiratory depression (slowed or shallow breathing). Concomitant use with specific inhibitors of liver enzymes can amplify this risk.

Q: Can Tilidin comp. STADA affect blood pressure?

A: While specific effects on blood pressure are not routinely listed, the regulatory documents do reference a potential for cardiovascular events as a serious adverse possibility.

Q: Can Tilidin comp. STADA affect a person's mood or cause emotional changes?

A: Yes, documented side effects include nervousness, which is a Frequent side effect. Changes in mood, such as euphoric mood, have also been reported with an unknown frequency.

Q: Are there any known effects of Tilidin comp. STADA during pregnancy or breastfeeding?

A: Use is generally not recommended during the second and third trimesters of pregnancy. Additionally, the regular use of the medicine is not recommended while breastfeeding.

Q: Why is Tilidin comp. STADA only available on prescription?

A: The medicine is a prescription-only product because it is a synthetic opioid analgesic. Due to its potency, potential for risk, and requirement for individualized dose management, it must be used under strict medical supervision.

Q: What kind of pain is Tilidin comp. STADA typically used to treat?

A: According to official indications, this combination medicine is prescribed for the treatment of severe pain.

Q: Is Tilidin comp. STADA used only for pain after surgery or injury?

A: No, while it may be used for acute severe pain, it is also indicated for the treatment of severe pain and is often used for long-term chronic management.

Q: Is Tilidin comp. STADA a narcotic or opioid medication?

A: The primary pain-relieving component, Tilidine, is classified as an Opioid Analgesic. In some regulatory contexts, this class of drugs may be generally referred to as narcotics.

Q: Is it possible for Tilidin comp. STADA to cause headaches?

A: Yes, official product information lists headache as a Frequent (Common) side effect of the medicine.

Q: Is it required to take Tilidin comp. STADA with food?

A: Official administration guidelines state that the intake of the medicine is generally independent of meals.

Q: Is it normal to sweat more while taking this medication?

A: Yes, increased sweating (hyperhidrosis) is documented as a Frequent (Common) side effect of the medicine.

Q: Are there studies comparing Tilidin comp. STADA to non-opioid pain relievers?

A: Research is noted to have examined the effect of the Tilidine component against other non-narcotic analgesics, such as Metamizole, in certain experimental pain models.

Q: Do children or teenagers ever get prescribed Tilidin comp. STADA?

A: The use of this medicine is strictly prohibited (contraindicated) for children under 14 years of age.

Q: Can Tilidin comp. STADA interact with blood thinning medications?

A: No specific blood thinners (anticoagulants) are directly listed as contraindications in the official documentation.

Q: Does Tilidin comp. STADA affect the kidneys?

A: Patients with severe renal impairment (severe kidney problems) require close medical monitoring. Official information specifies that special consideration is needed for this patient group.

Q: What is the maximum recommended dose of Tilidin comp. STADA?

A: The maximum recommended daily dose (MDD) of the Tilidine component, as specified in official product documents, is 600 mg.

How should Tilidin comp. STADA be stored and disposed of?

Official Storage and Disposal Requirements

This section outlines the non-advisory, labeled storage and disposal requirements for Tilidin comp. STADA, as stated in authoritative government regulatory documents.

Storage Conditions and Stability

Requirement	Official Statement
Temperature Limit	Do not store the medicine above +30 C.
Protection	Must be kept in the original packaging to protect the contents from moisture and must be used before the stated expiry date.
In-Use Stability	The oral solution form has an official 12-month shelf-life after first opening.
Child Safety	Must be kept out of the sight and reach of children. The oral solution container uses a child-resistant screw cap.

Disposal Instructions

To comply with environmental protection requirements, do not dispose of this medicine via wastewater (e.g., toilet or sink) or household trash. Unused or expired medication must be returned to a pharmacist or designated collection point.

Tilidin comp. STADA